About

About Great Bay Bio Great Bay Bio, headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal. We have platforms available: 1. AlfaDAX: AI + antibody developability assessment and optimization. 2. AlfaCell: AI + site-specific integration: Titer is guarantee 5 g/L for mAb and BsAb. From DNA to RCB only takes 1.5 months. The IND process can be saved up to 6 months. 3. AlfaOPA: AI + cell culture development without media screening: be able to develop the cell culture media within 1 month and the titer can be increased by more than 30%. About Great Bay Bio Limited Great Bay Bio, headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient", GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal. We have platforms available: 1. AlfaDAX: AI + antibody developability assessment and optimization. 2. AlfaCell: AI + site-specific integration: Titer is guarantee 5 g/L for mAb and BsAb. From DNA to RCB only takes 1.5 months. The IND process can be saved up to 6 months. 3. AlfaOPA: AI + cell culture development without media screening: be able to develop the cell culture media within 1 month and the titer can be increased by more than 30%. Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value. The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. The company operates a 3,000㎡ R&D laboratory and CMC platform, supporting customers in securing clinical trial approvals from China’s NMPA and the US FDA. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises. GBB has passed the ISO 9001:2015 quality management system certification, been selected for Forbes Asia 100 to Watch 2024 List, and won numerous awards, including "Deloitte Technology Rising Star Company," "EY Entrepreneur Of The Year," "15th Shenzhen Innovation & Entrepreneurship Competition," "Gold Award for Hong Kong Global Innovation," "Excellence in Process Innovation Award," and "Excellence in Technology Adoption Award". The company has also been successfully selected for the Hong Kong Science Park Elite Enterprise Program.